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Abstract
Background: The use of Microarray (array CGH) analysis has become a widely accepted front-line test replacing G
banded chromosome studies for patients with an unexplained phenotype. We detail our findings of over 5300 cases.
Results: Of 5369 pre and postnatal samples, copy number variants (CNVs) were detected in 28.3 %, of which ~40 %
were deletions and ~60 % were duplications. 96.8 % of cases with a CNV <5 Mb would not have been detected by G
banding. At least 4.9 % were determined to meet the minimum criteria for a known syndrome. Chromosome 17
provided the greatest proportion of pathogenic CNVs with 65 % classified as (likely) pathogenic. X chromosome CNVs
were the most commonly detected accounting for 4.2 % of cases, 0.7 % of these being classified as cryptic (likely)
pathogenic CNVs.
Conclusions: Microarray analysis as a primary testing strategy has led to a significant increase in the detection of CNVs
(~29 % overall), with ~9 % carrying pathogenic CNVs and one syndromic case identified per 20 referred patients. We
suggest these frequencies are consistent with other heterogeneous studies. Conversely, (likely) pathogenic X
chromosome CNVs appear to be greater compared with previous studies.
Background
The molecular karyotype (microarray) is now recognised
as a first tier diagnostic test for patients with wide-
ranging phenotypes and has led to greater sensitivity in
the detection of sub-microscopic genomic changes,
largely replacing microscopy for constitutional analysis
in many laboratories. Reported findings have varied due
mainly to sample numbers, different platforms, variation
in probe coverage and also analysis and reporting guide-
lines. Overall, as the technology has developed, it has
aided in the diagnosis of pathogenic copy number vari-
ants (CNVs) and also genotype-phenotype correlations.
Published reports tend to fall into three groups. First,
those based on sample sizes such as Park et al. [1] who
arrayed 407 peripheral bloods, and found an 8.3 % patho-
genic rate. Conversely, much larger scale array sample
numbers have included Shaffer et al. [2] who reported on
8800 patients with an overall CNV yield of ~12 %, and Ahn
et al. [3] who reported on a similar-sized sample number
with an overall CNV yield of ~25 %. Secondly, those fo-
cused on specific chromosomes such as Willemsen at al.
[4] who reported on X chromosome CNV studies and
found a pathogenic frequency of 0.3 %. Finally, small
cohorts of patients with specific phenotypes, such as those
described by Coutton et al. [5] and D’Arrigo et al. [6] who
studied children with varying degrees of intellectual disabil-
ity. These workers reported an overall CNV yield of ~30 %
and pathogenic yield of 16–21 %. We report the microarray
analysis of over 5300 New Zealand patients from a hetero-
geneous population of postnatal bloods, detail our findings,
outline some interesting case series, and compare our diag-
nostic yields to those reported by others.
Methods
Population & samples
The laboratory, based at Auckland City Hospital, serves
an area of the North Island of New Zealand with a popula-
tion of approximately 1.7 million. The demographics in-
clude a diverse ethnic mix including European Caucasian,
and a large Asia-Pacific population including indigenous
Maori, Pacific islanders & Han Chinese. Patients were re-
ferred from a variety of centres including paediatric,
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neonatal, outreach clinics and in-house clinical geneticists.
The age of patients were from newborn upwards, with re-
ferral reasons ranging from single or multiple congenital
abnormalities to neurodevelopmental delay with or with-
out neuropsychiatric disorders. From late 2014, following
national agreement, the laboratory expanded the service
to include prenatal testing on patients with two or more
abnormalities detected on ultrasound examination. A total
of 5369 samples were analysed up to the end of June 2015
including 230 products of conception (POC’s) and 40 pre-
natal samples. The patients, or parents in the case of neo-
nates, provided informed consent for diagnostic testing;
the New Zealand Health and Disability multi-region Eth-
ics Committee has ruled that cases of patient management
do not require formal ethics committee approval.
Array system details & methodology
Patient DNAs were screened for CNVs using either the
Affymetrix® Cytogenetics Whole-Genome 2.7 M Array
or the CytoScan® 750K Array. The former comprises
2.36M non-polymorphic markers and 400 k SNP
markers with an average probe spacing of 1 kb, and the
latter comprises 550 k non-polymorphic markers and
200 k SNP markers, with an average probe spacing of
4.1 kb. Practical procedures were carried out according
to the manufacturer’s instructions. In the case of the
2.7M array, this entailed whole genome amplification of
100 ng gDNA followed by purification. The purified
DNA was then fragmented, labelled and hybridised over-
night onto an array. The arrays were washed using an
Affymetrix® GeneChip® Fluidics Station, then scanned
using an Affymetrix® GeneChip® scanner. In the case of
the 750 K array, 250 ng gDNA was digested with Nsp1
and then ligated to a common oligonucleotide adaptor
for amplification by PCR. After purification, the PCR
products were fragmented and then labelled with a bio-
tinylated deoxynucleotide analogue using the TdT en-
zyme followed by overnight hybridisation to the array.
The arrays were washed using an Affymetrix® GeneChip®
Fluidics Station (which included DNA-selective staining
with a streptadivin conjugated reporter molecule) and
then scanned using an Affymetrix® GeneChip® scanner.
The data files generated for each sample were analysed
using Chromosome Analysis Suite (ChAS) Software
(v1.0.1 or v1.2.2). All results were subject to quality con-
trol for SNPQC, MAPD, waviness, sex, and signal inten-
sity. Samples which failed overall QC were repeated.
CNV interpretation
The clinical relevance of each CNV was assessed using the
guidelines described by the American College of Medical
Genetics, the ClinGen Structural Variant Working Group
(formerly the International Standards for Cytogenomic
Arrays Consortium) and the Australasian Society of
Diagnostic Genomics [7–9]. Primarily our approach
followed the evidence-based review process outlined by
Riggs et al. [8] and involved the assessment of published
data for, or against, dosage sensitivity of the genes within
each CNV. These data often included genotype/phenotype
correlations of previously documented cases, in vitro func-
tional data and pedigree segregation data. The outcomes
from these searches were added to data from publicly
available curated CNV databases and sequence mutation
databases for healthy or disease cohorts (DECIPHER data-
base, Database of Genomic Variants (DGV), Human Gene
Mutation Database). This information was used to classify
each region based on its expected clinical significance (be-
nign, likely benign, unknown, uncertain, likely pathogenic,
pathogenic).
Incidental findings are a category of variants present-
ing a unique set of challenges within the clinical envir-
onment [10] and are compounded by a lack of clarity of,
or difference in, the local medical ethics framework in
which the results are reported. There is currently an ab-
sence of agreement in the international community re-
garding best practice guidelines for reporting incidental
or secondary findings in general [11]. Incidental findings
were therefore handled on case-by-case basis in consult-
ation with the clinician.
Inheritance studies
Inheritance studies were primarily performed using BAC
FISH probes for the CNV of interest or, very rarely, by
microarray. Referral was made to our clinical genetic
service for counselling prior to follow up studies being
undertaken. In the case of more than one CNV being
detected in a proband, those CNVs of interest for further
investigation were selected by the clinical service. Only
237 cases were followed up, with confirmed de novo and
inherited frequencies of 95 and 161, respectively. Prior
to the advent of microarray technology insertional trans-
locations were thought to be very rare, with an estimated
occurrence of approximately 1/10,000 [12, 13]. Subse-
quently a frequency of 1/500 has been suggested [14].
Results
The scale of CNVs ranged from a 146 kb deletion to a
57.5 Mb terminal duplication. The latter was a dup(3)(p23q29)
detected in a male neonate with heart defects, clinodactyly
and dysmorphic features. Conversely, the 146 kb deletion
(18q21.3) was detected in a 16 year old presenting with
epilepsy, intellectual disability and hyperventilation. This
deletion contained part of the TCF4 gene and is associated
with Pitt-Hopkins syndrome (OMIM # 610954), which is
consistent with the referral reason.
We detected only one insertional translocation: a
16 year old girl with a history of developmental delay in-
cluding learning difficulties, dyspraxia and gross motor
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skills with a 2.1 Mb duplication of 9q34.3q34.3. Subse-
quent BAC FISH follow-up studies showed that this du-
plicated region was inserted into 19p13.4. Parental
analysis showed that this was inherited from her pheno-
typically normal father who had a balanced insertional
translocation.
Table 1, Fig. 1 and Table 2 document the overall CNV
findings, total number of CNVs as well as pathogenic
CNVs per chromosome, and the number of the most
common genomic syndromes, respectively. Our overall
reportable CNV detection frequency was 28.3 %, of
which ~40 % were deletions and ~60 % were duplica-
tions. Aneuploidy (such as Down, Edwards’ and Kleinfelter
syndrome) accounted for 0.7 % of cases. Initially samples
were processed for array analysis irrespective of whether
they were likely to be aneuploid. Subsequently, these sam-
ples were screened by FISH or G banding prior to being
arrayed, which resulted in a reportable CNV detection fre-
quency of 27.7 %. This adjusted figure is similar to the
25.2 % reported by Ahn et al. [3] who used an Agilent 4 ×
44 oligonucleotide array platform (AMADID 017457),
followed by an 8x60k platform (AMADID 028469), but
significantly greater than Shaffer et al. [2] who reported
~12 % using an unspecified BAC array platform. Previous
studies have shown that deletions are generally detected
more frequently than duplications with the suggestion that
duplications are associated with a milder phenotype and
are therefore less likely to be referred [15]; however, at
least one large scale study has shown a similar result to
ours, albeit with a larger overall CNV duplication detec-
tion frequency compared to deletions [3]. Apart from
chromosomal aneuploidy, approximately 171 cases (3.2 %)
carried a CNV greater than 5 Mb in size and would be de-
tected by G banding, while 96.8 % of cases would have
been below G banding resolution.
Eight hundred forty-two cases (15.7 %) were classified
as having a variant of unknown significance (VOUS),
with insufficient evidence to classify the CNV as patho-
genic, as well as insufficient information in the DGV
database to dismiss it as common within the normal
population. Four hundred sixty-two cases (8.6 %) were
classified as pathogenic. Approximately 45 % of the
pathogenic CNVs were categorised as likely pathogenic;
the majority met the minimum critical region (MCR) for
a recognised syndrome with wide-ranging variable pene-
trance with or without minimal phenotypic information.
Fifty-five percent of the pathogenic cases were described
as pathogenic on the basis of aneuploidy, large deletions
and structural rearrangements, known single gene hap-
loinsufficiency, or a minimum critical region for a syn-
drome with well-established and published penetrance
rates. 118 cases (2.1 %) were classified as unknown as
there were no similar cases within the peer-reviewed lit-
erature and inadequate evidence in databases of normal
variants to assist interpretation. Finally, approximately 101
reported CNVs (1.9 %) were classified as unlikely to be
pathogenic. Most of these CNVs comprised chromosomal
regions that were gene-poor and contained mainly non-
coding reference sequences with a complex phenotype.
Discussion
Previous postnatal studies have indicated that array
CGH and cytogenetic analysis detected pathogenic
chromosome abnormalities in ~7 % of children referred
for testing [2]. Our results indicate a pathogenic fre-
quency of 8.6 % for postnatal cases. The small number
of prenatal and products of conception cases (4.5 %)
would not have significantly influenced the abnormality
frequency (only 12 pathogenic), which consisted almost
exclusively of postnatal peripheral blood samples. The
frequency of 8.6 % compares to 6.9 % reported by
Shaffer et al. [2], and 8.3 and 9.8 % reported by Park et
al. [1] (who used a customised whole genome BAC
array) and Ahn et al. [3]), respectively. The guidelines
used by each of these groups for classification of the
CNVs were not specified.
We estimate that at least 262 of our pathogenic cases
(4.9 %) were consistent with a known syndrome (including
susceptibility loci or low penetrance syndromes) giving a
syndrome detection frequency of one per 20 cases, which
is the same as that reported by Ahn et al. [3]. A significant
proportion of these cases were confined to a small number
of chromosomes with 65 % (44) of CNVs detected on
chromosome 17 classified as pathogenic (Fig. 1). This
chromosome is predisposed to genomic rearrangements
Table 1 Overall findings of microarray testing
Number %





CNV >5 Mb 171 3.2
Mosaic 8 0.1
Pathogenic CNVs 462 8.6
Aneuploidy 37 0.7
Syndromes 262a 4.9
X Chromosome 75 1.4
Inheritance studies
No of cases 237 4.4
De novo 95 1.8
Maternal 103 1.9
Paternal 58 1.0
aAlso includes susceptibility loci/low penetrance
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having a large number of dosage-sensitive genes, together
with many interspersed nucleotide elements (LINEs/SINEs)
and segmental duplications (SDs) [16]. The other predom-
inant chromosomes carrying pathogenic CNVs were chro-
mosomes 22 which had 61 % of CNVs detected classified
as pathogenic, followed by chromosomes 16 (55 %), 1
(38 %), 15 (35 %), X (33 %), and 7 (31 %). Despite having a
large percentage of CNVs and also increased genomic size,
chromosome 4 CNVs were largely classified as VOUS, and
only nine were pathogenic.
The most common confirmed syndrome was 1q21.1
duplication syndrome(s), which included both the smaller
proximal (TAR syndrome) and larger proximal and distal
duplication syndrome regions (Table 2). The most com-
monly detected CNV occurred at 15q11.2, which contains
the TUBGCP5 [GCP5], CYFIP1, NIPA2 & NIPA1 genes.
Deletions of this region have variable penetrance, and are
associated with developmental and language delay, neuro-
behavioural disturbances and psychiatric problems; the
corresponding micro-duplication of this region has been
suggested to be a risk factor for some neurobehavioral
disorders [17]. Susceptibility loci and low penetrance syn-
dromes such as these make up 2.5 % of our detected CNVs.
4.9 % of reported CNVs involved the sex chromosomes
with the majority being on chromosome X and only 2
cases involving the Y chromosome being classified as
pathogenic. The Affymetrix platform lacks coverage of
the SRY gene, meaning that cryptic abnormalities involv-
ing this cannot be detected. Variants of the X chromo-
some form a subset due to dosage and also inheritance
differences between the sexes. Approximately 53 % (119)
of X chromosome CNVs (224) were classified as VOUS,
and 33 % (75) as (likely) pathogenic. Only 5 % (11) of X
chromosome CNVs were classified as unlikely to be
pathogenic, and almost exclusively were small CNVs in
females. Of the cryptic X chromosome CNVs classified
as VOUS, four cases (male) were found to be partial
AFF2 (FRAXE) gene duplications ranging from 101 to
135 kb. All of these cases carried an identical ~1.2 Mb
4q32.2q32.3 duplication, which contained part of the
MARCH1 gene. AFF2 gene duplications have been previ-
ously reported in the literature and have recently been
implicated in auditory processing, emotional impairment
and macrosomia [18]. The phenotypic spectrum of du-
plications of this gene (if any) is still not known. Three
of our four cases exhibited phenotypes encompassing
learning difficulties, microcephaly, developmental delay,
dysmorphic features, and bilateral sensorineural hearing
loss/audiology issues. The fourth case was part of a
follow-up study for another CNV, but this patient was
phenotypically normal. The DECIPHER database has a
very small number of partial and intragenic AFF2 gene
duplications, but phenotypic information on most of
these patients is not available. None of these cases had
an additional 4q2.2q32.3 CNV. MARCH1 is not covered
by DGV, and it is unknown if the MARCH1 duplication
represents a “double hit” or exhibits a modifier effect on
duplications of the AFF2 gene.
Approximately 38 of the pathogenic X chromosome
CNVs were aneuploid or large X chromosome abnor-
malities. Removal of these cytogenetically visible X
chromosome rearrangements gives a detection frequency
of 0.7 % for cryptic pathogenic CNVs, which is approxi-
mately double the frequency reported by Willemsen et
al. [4] in their study of the clinical relevance of X
chromosome CNVs. Their analysis was performed on
patients with cognitive disorders, with or without con-
genital anomalies, and mainly using the Affymetrix®
250 k SNP array & Agilent 32 k BAC array. These
workers suggested that relatively poor X chromosome
coverage may have led to smaller X chromosome CNVs,
such as those in the MECP2 gene, being missed. The
Fig. 1 Graphical illustration of the total number of CNVs detected per chromosome (Blue) alongside the number of pathogenic CNVs detected
per chromosome (Red)
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majority of our cryptic X chromosome CNVs ranged
from 100 to 800 kb in size (including two cases of Xq28 du-
plication encompassing theMECP2 and L1CAM genes). Of
the remaining 37 cryptic pathogenic X chromosome CNVs,
a small number of cases are of interest. Previously, SHOX
gene deletions have been implicated in Léri-Weill dyschon-
drosteosis (OMIM # 127300) and Langer mesomelic dys-
plasia (OMIM # 249700) [19]. We found a small
number of cases with agenic SHOX gene 3′ enhancer
deletions which were initially not reported by our
laboratory, but disruptions in this region are now
known to be pathogenic [20]. We subsequently de-
tected a 536Kb deletion in a patient with a complex
phenotype including short stature and involving a de-
letion of the entire SHOX gene 3′ enhancer region.
This represents the only agenic pathological CNV re-
ported by our service to date. A small number of
SHOX gene 5′ enhancer deleted CNVs have also been
found; however, the significance of CNVs in this re-
gion has not been determined.
Table 2 Numbers of the most common genomic syndromes detected among 5369 New Zealand patientsa
OMIM # Syndrome Number del x1 dup x3 trp x4
612474/612475 1q21.1c 31 9 22 -
612530 1q41q42 3 3 - -
612313 2q32 2 2 - -
609425 3q29 4 4 - -
194190 4p16.3 3 1 2 -
149730 LADD syndrome 2 2 - -
123450 Cri du Chat 1 1 - -
117550 Sotos 1 1 - -
194050/609757 7q11.23 16 12 4 -
613729 Distal 7q11.23 4 4 - -
610253 Kleefstra 2 2 - -
194072 WAGR (WT1) 1 1 - -
601803 Pallister-Killian 1 - - 1
615656 15q11.2c 37 21 16 -
105830/176270 AS/PWS 10 10 - -
612001 15q13.3c 17 17 - -
611913/614671 16p11.2c 29 21 7 1
613444 16p11.2c 5 5 - -
613604 16p12.2-p11.2c 1 1 - -
Hanner (2009) [22] 16p13.11c 13 6 7 -
614527/614526 17q12 (HNF1β) 12 5 7 -
610883 Potocki-Lupski 7 - 7 -
182290 SMS 1 1 - -
118220/162500 CMT/NHPP 6 5 1 -
247200/613215 17p13.3 5 3 1 1
610443/613533 17q21.31 5 3 2 -
613675 NF1 3 3 - -
115470 Cat eye syndrome 1 - 1 -
188400/192430 DGS/VCFS 13 13 - -
606232 Phelan McDermid 8 8 - -
312865/400020 SHOXb 3 3 - -
300260 MECP2 2 - 2 -
310200 DMD 2 2 - -
a The table uses the format reported by Ahn et al. [3]
b includes enhancer deletion of the SHOX gene
c susceptibility loci/low penetrance
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Rare X chromosome variants
A blood sample was received of a 2 year old boy with a
history of recurrent lymphadenitis, gastrointestinal in-
volvement with mild inflammation of the stomach, with
additional large intestine and perioral granulomatous
disease. An immunology work up showed a provisional
diagnosis of X-linked Chronic Granulomatous (OMIM #
306400). Microarray analysis showed a 109 kb deletion
of the CYBB gene consistent with X-linked Chronic
Granulomatous disease confirming the diagnosis. Finally
a 1 year old boy who had global developmental delay
carried a ~200 kb Xp21.3 deletion containing the
IL1RAPL1 gene, which is linked to non-specific X-linked
mental retardation [21]. Subsequent testing showed that
this deletion was inherited from his mother, as well as also
being found in three of her unaffected sisters. Skewed X
inactivation most likely accounted for phenotypic varia-
bility; however, further inheritance studies remain.
Both Coutton et al. [5] and D’Arrigo et al. [6] reported
their microarray analysis of small cohorts of patients
who had mild intellectual disability or developmental
delay according to specific criteria. Their CNV detection
frequency was approximately 30 %, with total pathogenic
CNV yields of 16 and 21 %, and pathogenic X chromo-
some yields of 1.5 and 2.1 %, respectively. Despite the
variation in sample sizes (60 vs 329), and geographic bias
to one referral centre [6], a global CNV detection fre-
quency of ~30 % is similar to our findings.
While specific phenotype studies have indicated a high
detection frequency for pathogenic CNVs, a number of
subsequent observations, including those reported here,
report that ~9 % may be the common frequency for
pathogenic CNVs detected in large scale heterogeneous
populations. Deviations from this frequency may be due
to the selection and enrichment of clinical phenotypes
that may lead to the over-representation of common
pathogenic regions such as those implicated in intellec-
tual disability.
Conclusion
Use of high resolution microarray platforms within our
population has allowed the detection of pathogenic CNVs,
as well as a significant number of cryptic pathogenic X
chromosome CNVs. The latter may be due to a number
of reasons. First, it represents a true reflection of the
higher abnormality frequency in our population compared
to others. Secondly, higher detection frequencies may be
platform-specific, which allows for the detection of
smaller pathological CNVs. Thirdly, we have been advan-
taged by the increased refinement of syndromic minimal
critical regions and phenotypes, coupled with the dis-
covery of additional new syndromes and pathological X-
linked genes (such as STAG2). We consider the latter two
reasons to be the most likely and so expect that detection
frequencies of ~29 % for overall CNVs and ~9 % for
pathogenic CNVs to be the minimum detection levels for
laboratories. It is anticipated that additional larger studies
in the future will match these detection frequencies, or
possibly exceed them in the case of pathogenic X-linked
disorders. The use of more targeted arrays in the future
may be necessary to increase pathogenic detection fre-
quencies. Our laboratory has recently implemented more
rigorous triaging of referrals for microarrays, and also
introduced the Affymetrix® Optima targeted array system
as a replacement for BACs-on-Beads™ (BOBs) for the
analysis of products of conception (POC). Both of these
measures are expected to increase the detection of patho-
genic CNVs.
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